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SU]VIMARY
Haemocyanin of Helix pomatia appeared to be a suitable antigen to measure
immune reactivity. In 12 healthy controls it induced an evident humoral and
cellular immune response as measured by haemagglutination titers and in vitro
lymphocyte stimulation by the antigen. Tl.ris response had characteristics of a
primary immune response: in the printary antibody response predominantly 2-ME
sensitive (l95) antibodies were induced, while in the secondary response mainly
2-ME resistant (7S) antibodies were elicited. In a series of controls of a later date,
consisting of 31 patients of the out-patient department with uncomplicated hyper-
tension or duodenal ulcer, who were immunized with diphtheria-tetanus toxoid and
sensitized with DNCB at the same time. low but evident 75 anti-HPH titers were
found in the prinrary response against HPH (mean titer 3 weeks after immunization,
I : 8). The total antibody titer appeared to be independent of age, while the 75
titer decreased and the 195 titer increased with ageing. The higher 75 titers in the
second series of controls may be caused by the simultaneous irnmunization with
diphtheria-tetanus toxoid and the sensitization with DNCB.
This haemocyanin (t{Ptt) revealed interesting alterations in primary immune
reactivity in patients with malignant melanoma. Concerning the relation between
immune reactivity and the clinical stage, only patients with wiciespread disease and
visceral metastases had altered irnmune reactivity, apparent from decreased 75
anti HPH antibody titers, decreased in vitro lymphocyte reactivity to HPH and
increased l9S titers. These results suggest that rnelanoma patients develop irnpaired
T-lymphocyte function in a late stage of the disease. This impairment is probably
caused by the tumour, maybe by specific or non-specific products fronr the tumour
or by a form of antigenic ornpetit ion by turnour antigens.
It was of interest that these patients with visceral metastases did not show an
impairnrent in the anamnestic antibody response to diphtheria or tetanus toxcid.
Using a serni-quantitative measurement of skin reactivity to DNCB, a decreased skin
reactivity was tbund after sensitization in patients with localized disease as well as
in patients with disseminated isease compared to that of age rnatched controls.
The frequency of completely negative DNCB sensitization tests, however, was not
increased in the patients. When immune reactivity of the patients with tumour
recurrence (10) within 6 rnonths after definit ive surgical therapy was compared to
that of patients witiout tumour recurrence (44), in vitro lymphocyte reactivity to
the test antigens (HPH, but also diphtheria and tetanus toxoid) was significantly
lower in patients with tunrour recurrence. No significant differences in skin
reactivity to DNCB was found between these groups. Although skin reactivity to
DNCB and in vitro lymphocyte reactivity to HPH are both considered as parameters
of cellular irnmunity, the discrepancy bctween the results obtained rvith these
primary antigens may be caused by differences in the antigenic composition as rvell
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as by different test methods. It was concluded that defects in lymphocyte function
in an early stage of malignant melanoma were related to subsequent tumour
growth. It will be interesting to investigate if lymphocyte reactivity to test antigens
will have prognostic value over a period longer than 6 months. From this study the
question arises if the observed defects in lymphocyte function can be improved by
immunotherapy and if this will lead to a better progÍIosis.
66
t_ q
